Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Pfizer Snagged Another Approval for This Immunology Drug
Pfizer Snagged Another Approval for This Immunology Drug
Pfizer Snagged Another Approval for This Immunology Drug
Submitted by
admin
on January 3, 2022 - 10:48am
Source:
Motley Fool
News Tags:
Pfizer
ankylosing spondylitis
Xeljanz
Headline:
Pfizer Snagged Another Approval for This Immunology Drug
snippet:
Pfizer's drug now has another market with tens of thousands of potential patients.
The ankylosing spondylitis indication in the U.S. could bring in over $200 million annually for Pfizer.
At a forward P/E ratio of less than 10, Pfizer is an attractive value proposition.
Do Not Allow Advertisers to Use My Personal information
